Market Signal Briefing

Veteran short-seller James Chanos has officially closed his high-profile trade shorting MicroStrategy (MSTR) while holding long positions in Bitcoin. The decision, announced on November 7, 2025, came after MicroStrategy’s premium to its Bitcoin holdings plunged from 2.5x to just 1.17x, signaling that the stock’s price had realigned more closely with the value of its underlying assets.

MicroStrategy currently holds 641,205 BTC worth approximately $65.4 billion, against a few billion dollars of debt. Despite this, the company’s market capitalization remains around $76 billion. Its stock is down 16% in 2025, while Bitcoin itself has gained about 9% over the same period. According to analysts, the now-closed trade yielded estimated returns of 15% to 35%, demonstrating disciplined market timing amid volatile conditions.

Market strategist Peter Duan noted that Chanos’s move underscores a critical investment lesson — the erosion of Wall Street’s traditional information edge. Duan emphasized that successful short-sellers like Chanos thrive by managing asymmetric risks and identifying overextended valuations. He pointed out that MSTR and Japan-based Metaplanet both saw parabolic, retail-driven rallies disconnected from their fundamentals. Low institutional ownership in these stocks made them attractive short targets, as retail sentiment amplified volatility and correlation with Bitcoin’s price movements.

While Duan remains bullish on the long-term prospects of Bitcoin Treasury companies like MicroStrategy and Metaplanet, he cautioned that investors continue to underestimate their operational complexities. With short pressure easing, MSTR’s next major move will likely depend on Bitcoin’s performance. The episode serves as a reminder of how deeply corporate Bitcoin strategies are now shaping equity market behavior.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Litecoin (LTC) has captured renewed investor attention after an impressive 17% rebound in just one day, showcasing strong resilience in the crypto market. Currently trading near $101.02, LTC is testing a key resistance level at $102 — a decisive zone that could determine its next major move. A confirmed breakout above this barrier may trigger a bullish reversal, paving the way for a rally toward $130 in the coming weeks. The price structure aligns with a long-term falling wedge pattern, suggesting growing momentum for an upward breakout.

If Litecoin fails to close above $102, however, a temporary pullback toward $85 could occur before buyers regain momentum. Still, the broader technical outlook remains favorable, supported by strengthening indicators. The Directional Movement Index (DMI) shows the +DI at 24.76 surpassing the -DI at 21.92, signaling bullish control. Meanwhile, the Average Directional Index (ADX) at 26.41 confirms an intensifying trend, while the MACD’s bullish crossover further validates increasing market momentum.

Despite mild profit-taking reflected in the Spot Taker CVD data, Litecoin’s price stability near resistance highlights sustained buying pressure. The recent launch of Canary Litecoin ETFs on NASDAQ adds further optimism, signaling increasing institutional demand for LTC. This influx of interest could solidify Litecoin’s breakout potential and drive a sustained rally if bulls maintain control.

Overall, Litecoin’s technical setup points to continued bullish momentum, with growing confidence among traders and institutions alike. A decisive close above $102 could confirm a major trend reversal, setting LTC on course for a strong move toward $130. As market sentiment strengthens and profit-taking stabilizes, Litecoin appears well-positioned to extend its recovery and confirm its next bullish phase.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Hedera’s native token, HBAR, continues to demonstrate impressive resilience despite facing multiple market crashes and failed recovery attempts. The altcoin remains steady above a key support level, bolstering investor confidence even as broader market sentiment leans bearish. However, uncertainty persists about how long HBAR can maintain this stability without stronger buying momentum.

The Chaikin Money Flow (CMF) indicator reveals that HBAR is still in the bearish zone below the zero line, signaling ongoing capital outflows. Although there has been a slight improvement, the inflows remain insufficient to shift market control away from sellers. This pattern suggests that until buying pressure consistently exceeds selling activity, HBAR’s price will stay under downward pressure. A gradual rise in inflows points to a slow return of investor interest, but it has yet to gain enough strength to influence the price trend decisively.

Similarly, the Relative Strength Index (RSI) supports this bearish outlook, staying below the neutral 50.0 mark. This indicates weak momentum and hesitation among traders to re-enter bullish positions. Without stronger market support, any short-term rally could face resistance and fail to sustain momentum. For HBAR to regain bullish traction, the RSI needs to move closer to neutral or above.

At present, HBAR trades at $0.174, just under the $0.175 resistance level. The token’s critical support sits at $0.162, a level that has successfully prevented deeper declines toward $0.154 in recent weeks. This zone continues to serve as a crucial foundation for potential recovery.

If overall market sentiment improves and capital inflows strengthen, HBAR could flip $0.175 into support, potentially sparking a rally toward $0.194 or even $0.200—marking a possible end to its current bearish phase.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Solana (SOL) continues its downward trajectory, extending investor losses as bearish sentiment grips the broader cryptocurrency market. Despite brief recovery phases in recent months, the altcoin now faces renewed selling pressure, largely influenced by its close correlation with Bitcoin’s price action.

Currently, Solana’s correlation with Bitcoin stands at an exceptionally high 0.97, indicating that SOL’s movements closely mirror those of the leading cryptocurrency. With Bitcoin trading near the $100,000 mark and struggling to break higher, Solana’s price outlook remains vulnerable. The lack of bullish momentum in Bitcoin has stifled Solana’s potential for independent growth, fueling investor uncertainty about the altcoin’s near-term stability.

From an on-chain perspective, Solana’s Net Unrealized Profit and Loss (NUPL) metric has slipped into the capitulation zone—a sign that many investors are holding assets at a loss. Historically, this zone has marked pivotal turning points for SOL, as investors tend to hold rather than sell during downturns, which can help slow further declines. However, given its strong dependency on Bitcoin’s market direction, Solana’s NUPL could deteriorate further if Bitcoin fails to stabilize.

At the time of writing, Solana trades around $157, continuing a month-long downtrend. If bearish momentum persists, SOL could slide toward $150 or even $146, levels that might trigger renewed buying interest and a potential rebound toward $163 or $175. However, if Bitcoin’s weakness deepens, Solana could fall below $146, potentially testing the $140 zone and invalidating short-term recovery expectations.

With market sentiment hinging on Bitcoin’s performance, Solana investors are watching closely for signs of stabilization before anticipating any meaningful recovery.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADS” or “ADSs”) of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased WPP ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP’s media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Continental Aktiengesellschaft (OTCPK:CTTAY) Q3 2025 Earnings Call November 6, 2025 6:30 AM EST

Company Participants

Max Westmeyer - Head of Investor Relations
Nikolai Setzer - Chairman of the Executive Board, Chief Sustainability Officer & CEO
Roland Welzbacher - CFO & Member of Executive Board

Conference Call Participants

Akshat Kacker - JPMorgan Chase & Co, Research Division
Christoph Laskawi - Deutsche Bank AG, Research Division
Horst Schneider - BofA Securities, Research Division
Monica Bosio - Intesa Sanpaolo Equity Research
Harry Martin - Sanford C. Bernstein & Co., LLC., Research Division
Thomas Besson - Kepler Cheuvreux, Research Division
Ross MacDonald - Citigroup Inc., Research Division
Michael Punzet - DZ Bank AG, Research Division
Michael Aspinall - Jefferies LLC, Research Division

Presentation

Max Westmeyer
Head of Investor Relations

Thank you very much. And welcome to all of you to our Q3 2025 results presentation. Today's call is hosted by our CEO, Nikolai Setzer; and our CFO, Roland Welzbacher. Both the press release and the presentation of today's call are available for download on our Investor Relations website. And I'd like to remind everyone that this conference call is for investors and analysts only. So if you do not belong to either of these groups, please disconnect now.

Following the presentation, we will conduct a Q&A session for sell-side analysts. [Operator Instructions] And before handing over, I want to briefly highlight some extraordinary effects that impacted our Q3 figures. As you're already used to it from the former AUMOVIO reporting, the signing of the sale of our original Equipment Solutions business within ContiTech has resulted in some accounting technicalities. Here, too, IFRS 5 applies and the assets and liabilities attributable to OESL were reclassified to assets and liabilities held for sale.

Furthermore, the sale has resulted in a write-down of the assets, which reduced the basis for depreciation. The depreciation of the new book values of

Recommended For You

NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. (NYSE: FCX) resulting from allegations that Freeport may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Freeport securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=45553 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On September 24, 2025, Freeport issued a press release entitled “Freeport Provides Update on PT Freeport Indonesia Operations.” It stated that Freeport “announced today an update on the status of the previously reported mud rush incident at the Grasberg Block Cave mine (GBC) in Indonesia. On September 20, 2025, PT Freeport Indonesia (PTFI) located two team members who were regrettably fatally injured in the September 8th incident.”

On this news, Freeport stock fell by 16.95% on September 24, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

November 08, 2025 6:14 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS" or "ADSs") of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased WPP ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP's media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273658

Consider it "game over" for the company's recent wave of meme stock mania.

The past several years have been rough for Beyond Meat (BYND +16.81%), but that didn't stop the plant-based meat company's shares from becoming one of the top meme stocks last month. In fact, Beyond Meat's precarious state may be the reason behind last month's meme mania.

However, flash forward to now, and shares have already retreated considerably. Although the company itself may survive, there could be more pain ahead for investors.

Today's Change

(

16.81

%) $

0.20

Current Price

$

1.39

A busted growth story for quite some time

Image source: Getty Images.

Up until the early 2020s, Beyond Meat was one of the most promising growth stocks. The rising popularity of plant-based diets pointed to further growth ahead. However, starting in 2021, the company's sales began to decline. This was due to a combination of competition from other alternative meat brands like Impossible Foods, coupled with the plant-based diet lifestyle trend peaking in popularity.

Already unprofitable, declining sales sank Beyond Meat deeper in the red. At first, existing cash covered these losses. Over the past two years, however, the company has had to sell more stock to raise money, leading to share dilution. Together, these factors caused shares to fall over 99% from their all-time high.

Why the meme stock run failed to last
Struggling and caught in a dilution spiral, Beyond Meat became a prime target for short-sellers. However, last month, as short interest spiked following the announcement of a highly dilutive debt restructuring plan, meme stock speculators started buying en masse to trigger a short squeeze.

This caused Beyond Meat to rally from around $0.55 per share to as much as $7.69 per share in a matter of days. However, after the company released lackluster preliminary quarterly results on Oct. 24, the "meme mania" quickly gave way to another massive sell-off.

What's next for Beyond Meat?
Thanks to the debt restructuring deal, Beyond Meat has staved off bankruptcy for now. However, unless the company quickly executes an effective turnaround plan, one that prioritizes profitability, the dilution spiral will likely continue. Existing shareholders would be wise to sell the stock; otherwise, stay away.

These funds could supercharge your passive income over time.

Dividend stocks are investments that pay a portion of profits back to shareholders, usually on a quarterly basis. A dividend exchange-traded fund (ETF) is a collection of dividend-paying stocks, all bundled together into a single investment.

By investing in a single dividend ETF, you can gain exposure to hundreds of stocks at once. The more shares you own, the more you'll receive in dividend payments -- potentially building a stream of passive income that pays thousands of dollars per year.

Not all dividend ETFs are created equal, but these three Vanguard funds can limit risk with ample diversification while paying out higher dividends.

Image source: Getty Images.

1. Vanguard Dividend Appreciation ETF
The Vanguard Dividend Appreciation ETF (VIG +0.14%) contains 337 stocks from companies with a history of increasing their dividend payments year after year. It pays quarterly dividends, and its most recent payment in early October was around $0.86 per share.

That may not sound like much, but once you've accumulated hundreds or even thousands of shares, it can add up. You also have the option to reinvest your dividend payments, making it easier to buy more shares. This can then have a snowball effect on earnings -- the more you invest, the more shares you'll own, the more you can reinvest in dividends, and so on.

Today's Change

(

0.14

%) $

0.29

Current Price

$

215.64

In addition to dividend payments, you'll also earn standard investment returns like you would with any other stock or ETF. This fund has earned an average rate of return of 12.83% per year over the last 10 years, which is slightly higher than the market's historic average of 10% per year.

2. Vanguard High Dividend Yield ETF
The Vanguard High Dividend Yield ETF (VYM +0.50%) is similar in many ways to the Dividend Appreciation ETF. It's focused on stocks from companies that have high dividend yields, and it most recently paid a quarterly dividend of around $0.84 per share.

The key differences between the two funds come down to their size and performance. The High Dividend Yield ETF contains significantly more stocks, with 566 holdings. Greater diversification can help limit the impact of volatility, giving this fund an edge for more risk-averse investors.

NYSEMKT: VYMVanguard Whitehall Funds - Vanguard High Dividend Yield ETF

Today's Change

(

0.50

%) $

0.70

Current Price

$

140.27

However, ETFs with more holdings can sometimes also earn lower returns, with lower-performing stocks dragging down the fund's total gains. Over the last 10 years, this fund has earned an average rate of return of 10.93% per year. While that's not a massive difference from the previous ETF's 12.83% average annual return, it can make a difference over time.

3. Vanguard International High Dividend Yield ETF
The Vanguard International High Dividend Yield ETF (VYMI +0.39%) contains stocks with the potential for above-average dividend yields, except it only includes international companies.

Investing in international stocks can have both advantages and risks. If you currently own only domestic companies, adding an international ETF can create more diversification. Sometimes, international markets are more favorable than the U.S. market, creating potential for higher returns.

That said, international stocks can sometimes be more volatile, too, especially during periods of economic or political instability. Just over 21% of the stocks in this particular ETF come from emerging markets, which are often less stable -- yet also have the potential for faster growth than developed markets.

Today's Change

(

0.39

%) $

0.33

Current Price

$

86.10

The International High Dividend Yield ETF issues quarterly dividend payments, which have experienced greater fluctuations between quarters. While the previous two ETFs had fairly consistent payments in the $0.85 to $0.95 per share range, this fund has paid dividends of between $0.60 and $1.07 per share this year alone.

In short, international stocks can be more lucrative, but there's also a higher chance of short-term volatility. If you're looking for international exposure and are comfortable with somewhat higher risk, this ETF could earn higher-than-average dividends over time while diversifying your portfolio.

Investing in dividend ETFs is a smart way to gain exposure to dividend stocks, add some diversification to your portfolio, and build a source of passive income at the same time. By investing consistently and gradually increasing your stake, you could build a passive income stream worth thousands of dollars per year.

GN Store Nord A/S (OTCPK:GNNDY) Q3 2025 Earnings Call November 6, 2025 5:00 AM EST

Company Participants

Rune Sandager - Head of Investor Relations
Peter Karlstromer - Chief Executive Officer
Soren Jelert - Chief Financial Officer

Conference Call Participants

Andjela Bozinovic - BNP Paribas, Research Division
Carsten Madsen - Danske Bank A/S, Research Division
Veronika Dubajova - Citigroup Inc., Research Division
Martin Parkhoi - SEB, Research Division
Niels Granholm-Leth - DNB Carnegie, Research Division
Martinien Rula - Jefferies LLC, Research Division
Susannah Ludwig - Sanford C. Bernstein & Co., LLC., Research Division
Julien Ouaddour - BofA Securities, Research Division
Martin Brenoe - Nordea Markets, Research Division
Richard Felton - Goldman Sachs Group, Inc., Research Division
Oliver Metzger - ODDO BHF Corporate & Markets, Research Division

Presentation

Rune Sandager
Head of Investor Relations

Hello, everyone, and welcome to GN's conference call in relation to our Q3 report announced this morning. Participating in today's call is Group CEO, Peter Karlstromer; Group CFO, Soren Jelert; and myself, Rune Sandager, Head of Investor Relations.

The presentation is expected to last about 20 minutes, after which we'll turn to the Q&A session. The presentation is already uploaded on gn.com. And with that, I'm happy to hand over to Peter for some opening remarks.

Peter Karlstromer
Chief Executive Officer

Thank you, Rune, and thanks to all of you for joining us today. Let me start with the group highlights on Slide 4. In Q3, we delivered a solid quarter with 1% organic revenue growth, driven by market share gains and strong performance across our divisions.

Our execution led to a healthy margin and cash flow development, allowing us to reconfirm our guidance for the year. In Hearing, the rollout of ReSound Vivia is continuing progressing very well. Vivia's strong differentiation and our solid commercial execution led to broad-based market share gains and 7% organic growth.

Overall, we are

Recommended For You

SES S.A. (OTCPK:SGBAF) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Christian Kern - Head of Investor Relations Adel Al-Saleh - Chief Executive Officer Elisabeth Pataki - Chief Financial Officer Conference Call Participants Paul Sidney - Joh. Berenberg, Gossler & Co. KG, Research Division Terence Tsui - Morgan Stanley, Research Division Ben Rickett - New Street Research LLP Roshan Ranjit - Deutsche Bank AG, Research Division Nick Dempsey - Barclays Bank PLC, Research Division Aleksander Peterc - Sanford C.

Simon Pryce
CEO & Executive Director

Thanks very much, and good morning, everyone. Welcome to the RS Group Interim Results Call for the 6-month period ending 30th September 2025, and thank you all for joining us this morning.

The presentation should take around 30 minutes, and then we'll have some time at the end for questions. But we'll try and make sure that we finish the call by no later than 10:00.

I'm going to start by summarizing our pleasing first half performance. Kate will then run through our in-line financials and what's driving them, both at a group and a regional level. Then I'll conclude by sharing with you the good underlying progress that we're making as we make the business better at RS and position ourselves to accelerate growth, improve efficiency, and drive better operating leverage over time.

But before we get into the details of this morning's presentation, we'd like to start our meetings, virtual or physical, at RS with a health and safety moment and a values highlight. So although we're virtual, please make sure you do take a safety moment to identify your nearest exit and safest evacuation route in the event of an emergency.

For our values highlight, I would just like to call out and celebrate our new multi-year global partnership with SolarAid to support their mission to light up lives across rural Africa. As our new global charity partner, their and our purposes and values are completely aligned that is one team delivering brilliantly, doing the right

Caterpillar Inc. (CAT) Analyst/Investor Day November 4, 2025 10:00 AM EST

Company Participants

Alex Kapper - Vice President of Investor Relations
Joseph Creed - CEO & Director
Jason Kaiser - Group President
Anthony Fassino - Group President of Construction Industries Group
Denise Johnson - Group President of Resource Industries
Bob De Lange - Group President of Services, Distribution & Digital
Andrew R. Bonfield - Chief Financial Officer

Conference Call Participants

Jamie Cook - Truist Securities, Inc., Research Division
Angel Castillo Malpica - Morgan Stanley, Research Division
Kyle Menges - Citigroup Inc., Research Division
Jerry Revich
Jairam Nathan - Daiwa Securities Co. Ltd., Research Division
Mircea Dobre - Robert W. Baird & Co. Incorporated, Research Division
Stephen Volkmann - Jefferies LLC, Research Division
Charles Albert Dillard - Sanford C. Bernstein & Co., LLC., Research Division
Robert Wertheimer - Melius Research LLC
Michael Feniger - BofA Securities, Research Division
Adam Seiden - Barclays Bank PLC, Research Division
Kristen Owen - Oppenheimer & Co. Inc., Research Division
Steven Fisher - UBS Investment Bank, Research Division
Tami Zakaria - JPMorgan Chase & Co, Research Division
Sabahat Khan - RBC Capital Markets, Research Division
Michael Shlisky - D.A. Davidson & Co., Research Division

Presentation

Alex Kapper
Vice President of Investor Relations

Good morning, everyone, and welcome to Caterpillar's 2025 Investor Day, the next 100 years. I'm Alex Kapper, Vice President, Investor Relations, and we're pleased to host you, whether you're joining online or in the room. And we're really excited to share with you how we see the next chapter of our story unfold. Just a few quick reminders before we get started. We've already conducted the safety briefing here in the room, and so I'd encourage anyone joining remotely to be aware of their surroundings and their local safety protocols.

During our event today, we'll make forward-looking statements, which are subject to risks and uncertainties. We'll make assumptions that could cause our actual results to be different

Recommended For You

, /PRNewswire/ -- A record-breaking field of more than 17,500 runners filled the streets of downtown Indianapolis today for the 18th annual CNO Financial Indianapolis Monumental Marathon, Half Marathon and 5K. The 13th consecutive sellout of the event showcased elite performances, including a new men's marathon course and event record and 14 athletes achieving qualifying times for the 2028 U.S. Olympic Team Trials – Marathon.

The Men's Champion, Joseph Whelan, broke the tape in 2:12:29, setting a new men's marathon course record and solidifying his place among the fastest marathoners ever to race in Indianapolis. On the women's side, Amanda Mosborg delivered a victory in 2:32:01, leading a strong field of competitors that included several returning champions and Trials qualifiers.

In total, 14 athletes earned 2028 U.S. Olympic Team Trials qualifying marks in the marathon distance, further establishing the CNO Financial Indianapolis Monumental Marathon as a key stop on the national competitive circuit.

Beyond the elite performances, the 2025 event featured a new start line on West Street, the largest marathon field in event history and the 10th anniversary of CNO Financial Group's title sponsorship. More than 6,600 marathoners earned their finisher medals and participants represented all 50 states and 22 countries, underscoring the event's growing global reach.

Results:

CNO Financial Indianapolis Monumental Marathon
Men's Champion: Joseph Whelan of Webster, N.Y., broke the finish tape and set a new course record with a winning time of 2:12:29. Ben Decker of Cambridge, Mass., and Andrew Bowman of Ferndale, Mich., finished second and third in a time of 2:15:23 and 2:15:33, respectively.

Women's Champion: Amanda Mosborg of St. Paul, Minn., finished first overall in a time of 2:32:01. Lucy Dobbs of Indianapolis crossed the line second with a time of 2:32:42, and Anna Benedettini of Virginia Beach, Va., finished third, coming in at 2:33:12.

CNO Financial Indianapolis Monumental Half Marathon
Men's Champion: Skylar Stidam of Bloomington, Ind., led the men's race and finished first in a time of 1:02:47. Second-place finisher Curtis Eckstein of Batesville, Ind., ran a time of 1:03:06, and third-place finisher Alec Basten of St. Louis, Mo., crossed the line in a time of 1:03:15.

Women's Champion: Carrie Ellwood of Boulder, Colo., won the women's race in a time of 1:08:33. Kasandra Parker of Waverly, Iowa, finished in second place with a time of 1:10:18, and Molly Grabill of Lafayette, Colo., finished in third at 1:11:00.

CNO Financial Indianapolis Monumental 5K
Men's Champion: Scott Spaanstra of Indianapolis, in 14:38.
Women's Champion: Sammy McClintock, Flagstaff, Ariz., in 16:17.

Other Highlights:

The 2025 event featured the 13th consecutive sellout and welcomed 17,500 participants from every U.S. state and 22 countries.
For the second consecutive year, the CNO Financial Indianapolis Monumental Marathon featured a record number of marathon finishers in the largest field ever.
Beyond Monumental's Run for a Cause program saw more than 240 participants run with a charity, such as Team World Vision, American Foundation for Suicide Prevention, International Justice Mission and more, all of which served to raise funds and awareness as they trained for the race.

This marks CNO Financial Group's 10th year as the title sponsor of its hometown marathon. CNO's partnership with Beyond Monumental underscores the organizations' shared commitment to health, wellness and the central Indiana community. The sponsorship continues to provide significant growth opportunities for Indy's premier running event.

Full results, when available, can be found here.

Plans are already underway for next year's event, scheduled for Saturday, Nov. 7, 2026. Participants can secure their spot for 2026 this weekend at monumentalmarathon.com. Registration closes Sunday, Nov. 9 and will reopen for the tradition of special Monumental Resolution pricing on Jan. 1, 2026.

About Beyond Monumental
Beyond Monumental, the 501(c)3 non-profit responsible for the CNO Financial Indianapolis Monumental Marathon, provides the Indianapolis community with a complement of activities built around their premiere event that promotes healthy living & fitness for all ages. Beyond Monumental gives back to the Indianapolis community by supporting youth programming that reinforces healthy lifestyles for young people, with an emphasis on working with urban students and Indianapolis Public Schools, donating over $1.7 million since inception. The CNO Financial Indianapolis Monumental Marathon is a top 15 marathon in the US and is nationally recognized by Runners' World as one of "Ten Great Marathons for First Timers". The 19th annual running is scheduled for Nov. 7, 2026. For more information, please visit beyondmonumental.org.

About CNO Financial Group
CNO Financial Group, Inc. (NYSE: CNO) secures the future of middle-income America. CNO provides life and health insurance, annuities, financial services and workforce benefits solutions through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income and retirement needs with 3.3 million policies and $38.3 billion in total assets. Our 3,300 associates, 4,900 exclusive agents and more than 6,500 independent partner agents guide individuals, families and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.

SOURCE CNO Financial Group

Amazon (NASDAQ:AMZN) absolutely knocked one out of the ballpark this quarterly earnings season.

NEW YORK, Nov. 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of America’s Car-Mart, Inc. (NASDAQ: CRMT) resulting from allegations that America’s Car-Mart, Inc. may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased America’s Car-Mart, Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On September 4, 2025, during market hours, Benzinga published an article entitled “America’s Car-Mart Stock Plunges After Sales Volume Dip, Delinquency Uptick.” The article stated that America’s Car-Mart, Inc. stock was trading “lower after the company reported first-quarter results. The company reported a first-quarter loss of 69 cents per share, compared with a net loss of 15 cents per share in the year-ago period.”

On this news, America’s Car-Mart, Inc. stock fell 18.2% on September 4, 2025.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile –

− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac Parameters –

– In a Cohort of HELIOS-B Patients, CMR Imaging Showed Amyloid Regression in 22% of Vutrisiran Treated Patients with No Regression Found in Patients Who Received Placebo –

– Treatment with Vutrisiran Preserved Kidney Function in HELIOS-B Patients, and Reduced Risk of Death and Cardiovascular Events in Patients with Advanced Chronic Kidney Disease –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from cardiovascular magnetic resonance (CMR) and echocardiographic imaging as well as renal function analyses were presented at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana.

As a multisystem disease, ATTR-CM can impact the health and function of organs throughout the body. These analyses evaluated the effect of vutrisiran on critical measures of heart function and structure as well as kidney health, providing deeper insight into its potential impact on key organs affected by the disease.

HELIOS-B Analyses: Cardiac Structure, Function, and Amyloid Burden

In ATTR-CM, amyloid deposits in the heart lead to thickening and stiffening of the ventricles, affecting how well the heart functions and increasing the risk of heart failure and death. Advanced imaging techniques offer insights into structural and functional changes, capturing the overall burden of amyloid deposits and their impact on cardiac function.

A CMR analysis evaluated a retrospectively identified cohort of HELIOS-B patients from the National Amyloidosis Centre in London who underwent serial CMR scans as part of their routine clinical care at baseline (N=43), Year 1 (N=39), Year 2 (N=26), and Year 3 (N=17).

A mixed model analysis that pooled 24- and 36-month data found that treatment with vutrisiran monotherapy was associated with nominally statistically significant and directionally favorable changes in multiple measures of cardiac structure, function, and amyloid burden, including improvements in left and right ventricular ejection fractions as well as stroke volumes and left ventricular mass, compared to placebo.

Treatment with vutrisiran also reduced extracellular volume (ECV), which is thought to reflect amyloid buildup in the heart. At Year 3, amyloid regression, as assessed by ECV, was observed in 22% of patients treated with vutrisiran, while no patients who received placebo showed regression; conversely, progression occurred in 63% of patients who received placebo compared to 11% of patients treated with vutrisiran.

At Year 3, patients treated with vutrisiran exhibited an absolute mean (standard deviation) reduction in ECV of -0.10% (± 4.72) versus an increase of 7.86% (± 5.67) in the placebo group (p=0.006).

To further assess cardiac function in patients with ATTR-CM, echocardiographic parameters including left atrial strain (LAS) and right ventricular free wall strain (RVFWS) were evaluated in analyses of the overall HELIOS-B population.

The LAS analysis demonstrated that measures of LAS were associated with baseline disease severity, mortality, and cardiovascular (CV) events, and that patients treated with vutrisiran experienced less worsening in LAS at 30 months, compared to those receiving placebo.

The RVFWS analysis showed that worse RVFWS was associated with higher risk of adverse outcomes and that treatment with vutrisiran stabilized RVFWS at 30 months, compared to placebo.

“As ATTR-CM progressively damages the heart muscle, making it thicker, stiffer, and less capable of pumping blood effectively, patients experience worsening symptoms, quality of life, and outcomes,” said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. “The HELIOS-B CMR analysis provides compelling initial evidence that treatment with vutrisiran can counteract these changes in some patients, as shown by favorable impacts on measures of cardiac structure and function as well as regression of amyloid burden. These results suggest that vutrisiran has the potential not only to slow disease progression, but to reverse some of the structural damage caused by amyloid deposition in the heart in some patients.”

HELIOS-B Analysis: Renal Function and CV Outcomes in Patients with Severe Chronic Kidney Disease (CKD)

Kidney involvement is common in patients with ATTR-CM and is associated with disease progression along with worse patient outcomes as amyloid deposits in the kidneys can lead to a decline in kidney function, indicated by a decreasing estimated glomerular filtration rate (eGFR).

A post hoc analysis of the HELIOS-B study evaluated the impact of vutrisiran on renal function and assessed the efficacy and safety of vutrisiran in patients who advanced to severe CKD during the double-blind period. Outcomes, including the composite endpoint of all-cause mortality (ACM) and recurrent CV events, as well as safety, were assessed in patients who advanced to CKD Stage 4 or greater (eGFR < 30 mL/min/1.73 m²) in the overall population, vutrisiran monotherapy population, and baseline tafamidis treatment group.

In the overall population, treatment with vutrisiran resulted in fewer patients experiencing ≥40% decreases in eGFR from baseline during the double-blind period, compared to placebo (12.7% vs 21.2%).

In patients in the overall population who progressed to CKD Stage 4 or greater during the double-blind period, treatment with vutrisiran reduced the risk of ACM and CV events (hazard ratio [HR] 0.47; 95% confidence interval [CI]: 0.26–0.85), compared to placebo.

In both analyses, results observed in patients who progressed to CKD Stage 4 or greater were consistent across the overall population, vutrisiran monotherapy, and baseline tafamidis treatment groups, and were also consistent with vutrisiran’s established efficacy profile from the primary HELIOS-B analysis.

The safety profile of vutrisiran in patients who advanced to CKD Stage 4 or greater was comparable with that established in the overall population of the HELIOS-B study.

“The new HELIOS-B analyses add depth to the growing body of evidence supporting AMVUTTRA’s first-line potential in ATTR-CM treatment,” said John Vest, M.D., Senior Vice President, TTR Global Clinical Lead, Alnylam. “From heart structure and function to renal health, the benefits observed are consistent across a wide range of measures and analyses, underscoring the potential for protection of the multiple organs impacted by this systemic disease. These findings build on the broadening dataset from HELIOS-B and continue to support the potential of AMVUTTRA to provide meaningful clinical benefit for patients living with this rapidly progressive multisystem disease.”

Data from the HELIOS-B study supported the approvals of AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary ATTR-CM in adults in the United States (US), Brazil, European Union (EU), Japan, United Arab Emirates (UAE), United Kingdom (UK), and Switzerland. AMVUTTRA is an RNAi therapeutic that works upstream to deliver rapid knockdown of transthyretin, addressing the disease at its source, with four subcutaneous doses per year. Collectively, AMVUTTRA has more than 8,000 patient-years of experience worldwide and is the first RNAi therapeutic approved for the treatment of both ATTR-CM and hATTR-PN in adults.

For additional information on Alnylam’s presentations in ATTR-CM at the AHA 2025 Scientific Sessions, please visit Capella.

Indications and Important Safety Information

Indications Approved by the U.S. FDA

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.

polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full U.S. Prescribing Information (revised March 2025)

About AMVUTTRA

AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. It is marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and it is also approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults in the US, EU, UK, Brazil, Japan, Switzerland, and UAE. In a clinical study, AMVUTTRA rapidly knocked down TTR in as early as six weeks and decreased TTR levels by 87% with two and a half years of treatment. Administered quarterly via subcutaneous injection, AMVUTTRA is the first and only RNAi therapeutic approved for the treatment of both the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR).

About ATTR

Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000 – 300,000 people worldwide.1-4

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today.5 Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine.6 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made.5 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio® (inclisiran) and Qfitlia™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

Alnylam Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam’s expectations regarding the safety and efficacy of vutrisiran as a treatment for ATTR-CM, including vutrisiran’s impact on measures of cardiac structure and function; the potential for treatment with AMVUTTRA to result in regression of amyloid burden in some patients; the potential of AMVUTTRA to slow disease progression and to reverse some of the structural damage caused by amyloid deposition in the heart in some patients; the potential impact of vutrisiran on key organs affected by ATTR-CM; AMVUTTRA’s potential to be a first-line treatment for ATTR-CM; AMVUTTRA’s potential to protect multiple organs impacted by ATTR-CM and to deliver meaningful clinical benefit for patients living with ATTR-CM; and Alnylam’s ability to execute on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to Alnylam’s ability to successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; the possibility of unfavorable new clinical data and further analyses of existing clinical data; interim and preliminary data; the possibility that clinical data are subject to differing interpretations and assessments by regulatory agencies; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam’s approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam’s product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation; the potential risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing Alnylam’s views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

References

1 Hawkins PN, Ando Y, Dispenzeri A, et al. Ann Med. 2015;47(8):625-638.

2 Gertz MA. Am J Manag Care. 2017;23(7):S107-S112.

3 Conceicao I, Gonzalez-Duarte A, Obici L, et al. J Peripher Nerv Syst. 2016;21:5-9.

4 Ando Y, Coelho T, Berk JL, et al. Orphanet J Rare Dis. 2013;8:31.

5 Elbashir SM, Harborth J, Lendeckel W, et al. Nature. 2001;411(6836):494-498.

6 Zamore P. Cell. 2006;127(5):1083-1086.

More News From Alnylam Pharmaceuticals, Inc.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2026.

So what: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about Inspire V, a sleep apnea device, including the actual market demand for the device and whether Inspire Medical had taken the steps necessary to launch it. Defendants issued a series of materially false and misleading statements that led investors to believe that demand for Inspire V was strong and that Inspire Medical had taken the necessary steps for a successful launch. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the on.

Short-seller James Chanos has closed his short position against Strategy after the firm's premium over its bitcoin holdings shrank, validating his bearish thesis.

The cryptocurrency market is once again under pressure, with Bitcoin (BTC) struggling to hold above critical support levels. After a brief recovery in October, BTC has slipped nearly 6% over the past week, according to CoinGecko data.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Cardano price surged by 10% amid renewed interest from retail investors, signaling a potential shift in market sentiment. ADA is currently holding strong above the crucial $0.50 support level, showing resilience despite recent market volatility. 

This price action comes as the broader crypto market rebounded slightly, gaining 0.73% after experiencing a significant weekly pullback. Buyers have begun stepping in, defending the key support zone and hinting at renewed bullish momentum. The price now consolidates within a narrowing range, pointing to an imminent breakout opportunity.

Cardano Price Eyes $1 Target as Accumulation Trend Gains Momentum
Cardano price may be preparing for a rebound after significant market movements this week. Reports indicate that large holders, known as whales, have offloaded around 4 million ADA. However, this selling pressure appears to be easing, while smaller investors are beginning to accumulate tokens again. Analysts predict Cardano price recovery, which this shift could signal the start of a bullish phase.

Market indicators also show growing confidence. Open interest and derivatives activity are trending bullish, hinting at renewed optimism among traders. With retail investors re-entering and buying pressure strengthening, some market watchers are eyeing a potential move toward the $1 mark. Whether ADA can sustain this momentum remains to be seen, but sentiment across the market is clearly improving.

$ADA Update: Whales sold 4M ADA, but retail accumulation & rising taker buy dominance hint a $1 target

Signs of a shift:

• Whale pressure easing

• Retail re-entering

• Open Interest & derivatives bullish

Could this be the start of ADA’s rebound?

Shared Via @coinexcreators pic.twitter.com/E2lONrgwn5

— Jack (@WispOfDeFi) November 8, 2025

Is ADA Price Preparing for a Major Breakout Above $0.60?
The latest ADA price surged to $0.5626, with more than 10% in the past session.  The 4-hour chart reveals that ADA is stabilizing between the $0.50 support and the $0.60 resistance range. 

If ADA sustains above $0.55, the next resistance levels are seen around $0.70, $0.80, and $1.00. As the crypto market recovers, the full Cardano forecast report is bullish.

Source: ADA/USD 4-hour chart: Tradingview
However, failure to hold this level could push prices back toward the $0.50 and $0.45 support zones.  The MACD indicator currently shows a mild bullish crossover, with the MACD line slightly above the signal line. This suggests improving momentum, though strength remains limited. A continued rise in the histogram bars could confirm an ongoing short-term uptrend. The Relative Strength Index (RSI) stands at 52, hovering near the neutral zone.

Ethereum's price rebounded to nearly $3,500 on a recent Friday, marking a 4.5% increase after initially dipping to $3,200. Despite these fluctuations and an overall decline throughout the month, analysts continue to express optimism about the cryptocurrency's potential for growth.

Trump Media and Technology Group (TMTG) now holds more than 11,500 Bitcoin worth over $1.3 billion, yet the company continues to post steep losses.Meanwhile, several Trump-linked ventures have simultaneously expanded their crypto exposure, bringing their combined holdings into the multibillion-dollar range.The trend reflects a coordinated political and commercial push to frame digital assets as both a strategic reserve and a core part of the administration’s policy agenda.Trump Media and Technology Group (TMTG), the media company associated with US President Donald Trump, now holds more than 11,500 Bitcoin, valued at over $1.3 billion.

The disclosure marks the company’s largest confirmed allocation to date and places it among the biggest public-sector corporate holders of Bitcoin.

Sponsored

Sponsored

TMTG Bitcoin Holdings Fail to Yield GainsTMTG accelerated its pivot earlier this year when it formally adopted Bitcoin as a core reserve asset.

At the time, TMTG said the company turned to BTC to protect itself from what he described as harassment and discriminatory treatment by financial institutions.

That argument tied Trump Media’s strategy to a wider corporate trend in which firms use Bitcoin to limit perceived dependence on banks that can freeze, slow, or scrutinize accounts.

Trump Media’s Bitcoin Holdings. Source: SECMeanwhile, the company’s holdings extend beyond Bitcoin. TMTG reported owning roughly 756 million Cronos (CRO) tokens, worth approximately $110 million.

The position reflects the company’s growing alignment with Crypto.com, a relationship that has already produced several crypto-focused initiatives, including exchange-traded products and promotional tie-ins.

These initiatives helped position TMTG as a more active participant in the crypto economy, even though they have not reversed the firm’s financial challenges.

Sponsored

Sponsored

TMTG posted a $54.8 million net loss in the third quarter of 2025, extending its stretch of multi-million-dollar quarterly losses.

This suggests that the company’s crypto-heavy strategy has therefore served more as a political and operational statement than a source of near-term financial relief.

Trump’s Family Crypto Holdings SurgeAs TMTG increased its exposure, other Trump-connected ventures expanded theirs as well, creating a broader cluster of politically adjacent crypto holdings.

Data from Arkham Intelligence indicates that several affiliated entities now hold substantial balances.

Other notable Trump Family entities:

Donald Trump: holds $861K in crypto
World Liberty Fi: holds $5.76B in crypto
Official Trump Meme: holds $6.30B in crypto
Official Melania Meme: holds $19.65M in crypto
Trump Cards: holds $29.72K in crypto pic.twitter.com/T12F6yP4Oh

— Arkham (@arkham) November 8, 2025
Trump personally holds about $861,000 worth of digital assets, while World Liberty Financial, one of the largest Trump-associated projects, controls more than $5.7 billion in crypto.

Additional holdings include $6.3 billion tied to Official Trump Meme, $19.65 million linked to Official Melania Meme, and nearly $30,000 associated with the Trump Cards collection.

These positions grew as the White House intensified its pro-crypto messaging, which shaped both the political environment and the commercial incentives for Trump-aligned ventures to deepen their involvement.

Taken together, the holdings show a coordinated embrace of digital assets across Trump-linked entities. They also reflect the administration’s broader effort to position crypto as both a strategic asset and a policy priority.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.